XenoPort reported midstage trial results showing that XP19986, a treatment for gastroesophageal reflux disease, did not demonstrate a significant difference versus placebo in decreasing heartburn. The company said it intends to conduct further studies after finding that the drug worked in patients who benefited at least partially from proton pump inhibitors.

Full Story:
Reuters, Bloomberg

Related Summaries